FDA Reorganization Adds "Directorate" Layer, But Sharpens Agency's Focus

Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the drug and biologic review centers intact but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.